Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Interest & Investment Income: 2016-2025

Historic Interest & Investment Income for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Sep 2025 value amounting to $366,000.

  • Lineage Cell Therapeutics' Interest & Investment Income fell 7.81% to $366,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2.03%. This contributed to the annual value of $1.7 million for FY2024, which is 5.28% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Interest & Investment Income stood at $366,000 for Q3 2025, which was down 19.38% from $454,000 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Interest & Investment Income registered a high of $478,000 during Q1 2025, and its lowest value of $2,000 during Q1 2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $410,000 (2023), whereas its average is $422,000.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 99.51% in 2021, then grew by 21.20% in 2024.
  • Over the past 4 years, Lineage Cell Therapeutics' Interest & Investment Income (Quarterly) stood at $2,000 in 2021, then reached $404,000 in 2023, then decreased by 2.72% to $393,000 in 2024, then declined by 7.81% to $366,000 in 2025.
  • Its Interest & Investment Income stands at $366,000 for Q3 2025, versus $454,000 for Q2 2025 and $478,000 for Q1 2025.